Not always. In stage 1, surgery is usually enough; in stage 2, chemotherapy is offered only to patients whose tumour has high-risk features; and in stage 3, when the cancer has reached the lymph nodes, chemotherapy after surgery is standard and increases the chance of survival [2, 3]. For many stage 3 patients at lower risk, 3 months of treatment works as well as 6 months [7, 8]. It is best to start treatment within the first 8 weeks after surgery [2].
Key points
- Chemotherapy after surgery aims to destroy cancer cells that may have stayed in the body after the operation [1]; not every patient needs it.
- Stage 1: the treatment is surgery, and almost all patients are alive 5 years later with surgery alone [2, 19].
- Stage 2: chemotherapy is normally offered only when the tumour has high-risk features; for example, when it has grown through the bowel wall [2, 3].
- Stage 3: chemotherapy after surgery is standard, and for many patients at lower risk, 3 months of treatment is enough [2, 7].
- An MSI or MMR test on the tumour changes the decision in stage 2: these tumours have a low risk of coming back and usually do not need chemotherapy [2, 3].
- Do not start late: it is best to start chemotherapy within the first 8 weeks after surgery [2].
What does chemotherapy after surgery achieve?
Surgery removes the tumour and usually the lymph nodes next to the bowel [19]. Chemotherapy after surgery aims to destroy cancer cells that may have stayed in the body, to lower the chance of the cancer coming back [1]. Your doctor weighs up the risk of your cancer coming back, the likely benefit of chemotherapy and the risk of side effects, and discusses all of this with you [2].
The higher the risk of the cancer coming back, the greater the benefit of chemotherapy. According to the European guideline, in stage 3 chemotherapy prevents 10 to 15 deaths for every 100 patients, and adding the drug oxaliplatin prevents another 4 to 5; in high-risk stage 2 the figure is about 3 to 5 deaths for every 100 patients [2].
For physicians
ESMO 2020: 5-year survival after surgery alone is 99% in stage I, 68% to 83% in stage II and 45% to 65% in stage III; adjuvant therapy lowers the risk of death by an absolute 3% to 5% in high-risk stage II with single-agent 5-FU and by 10% to 15% in stage III with a fluoropyrimidine alone, with a further 4% to 5% from oxaliplatin-containing regimens [I, A]; adjuvant options should be fully discussed with the patient, taking into account the risk of recurrence, the expected benefit and the risk of complications [2]. QUASAR (3,239 patients, 91% stage II; fluorouracil and folinic acid vs observation): RR of death 0.82 (95% CI 0.70 to 0.95) and RR of recurrence 0.78 (0.67 to 0.91); assuming 20% 5-year mortality without chemotherapy, an absolute survival gain of 3.6% (1.0 to 6.0) [4]. MOSAIC (2,246 patients with stage II or III; FOLFOX4 vs LV5FU2): 5-year DFS 73.3% vs 67.4% (HR 0.80); 6-year OS in stage III 72.9% vs 68.7% (HR 0.80); no OS difference in stage II [6].
By stage: who needs chemotherapy?
| Stage | What it means | Chemotherapy after surgery |
|---|---|---|
| Stage 1 | The cancer is in the inner layers of the bowel wall and has not reached the lymph nodes [19] | Usually not needed; almost all patients are alive 5 years later with surgery alone [2, 19] |
| Low-risk stage 2 | The cancer has grown through the muscle layer of the bowel wall but has not reached the lymph nodes and has no high-risk features [19] | Usually not needed; regular follow-up [2, 3] |
| Stage 2 with MSI-H or dMMR | A test on the tumour has shown a particular kind of DNA repair defect | Usually not needed; the risk of the cancer coming back is low and single-drug chemotherapy has not shown a benefit [2, 3, 5] |
| High-risk stage 2 | For example, the tumour has grown through the bowel wall or made a hole in it, fewer than 12 lymph nodes were examined, or the bowel was blocked [2, 3] | Offered; decided after discussion [2, 3] |
| Stage 3 | The cancer has reached the lymph nodes next to the bowel [19] | Yes, it is standard; 3 or 6 months [2, 7] |
The decision is based on the pathology report after surgery: how deep the tumour has grown, how many lymph nodes were examined and how many contain cancer, and the result of the MSI or MMR test [2]. If the cancer has spread to distant parts of the body (stage 4), treatment decisions are different.
To understand these terms better, see How to read your pathology report and Is bowel cancer curable?
For physicians
Stage II, ESMO 2020: major prognostic factors are fewer than 12 lymph nodes sampled and pT4 (including perforation); minor factors are high grade, vascular, lymphatic and perineural invasion, presentation with obstruction and a high preoperative CEA. Low risk: follow-up [I, A]; intermediate risk (no MSI/dMMR and any risk factor except pT4 or fewer than 12 nodes): 6 months of a fluoropyrimidine [I, B]; high risk (pT4 or fewer than 12 nodes or several intermediate factors, regardless of MSI): adding oxaliplatin may be considered [I, C], as may 3 months of CAPOX [II, B]. MSI/MMR is the only validated molecular marker for adjuvant decisions and should be determined in stage II [IV, A]; in dMMR stage II (10% to 15% of stage II patients) the risk of recurrence is very low and a fluoropyrimidine benefit has not been shown, so adjuvant chemotherapy is not indicated [I, A]; in pT4 with MSI the benefit of chemotherapy is uncertain. Gene expression signatures are not recommended for routine use [II, C] [2].
ASCO 2022: ACT is not routinely recommended in stage II without high-risk features; patients with T4 should be offered ACT; with other high-risk factors (fewer than 12 nodes, perineural or lymphovascular invasion, poorly or undifferentiated grade, obstruction, perforation, grade BD3 tumour budding) ACT may be offered; adding oxaliplatin is not routine but may be offered through shared decision-making; dMMR/MSI tumours should not routinely receive ACT, and if high-risk factors lead to a decision to treat, an oxaliplatin-containing regimen is recommended [3]. Sargent 2010 (457 patients with stage II and III, 15% dMMR): FU was beneficial in pMMR (DFS HR 0.67) but not in dMMR (HR 1.10); in the pooled data set of 1,027 patients, treatment of stage II dMMR was associated with reduced overall survival (HR 2.95; 95% CI 1.02 to 8.54) [5]. Tool: Colon cancer TNM staging.
Stage 3: 3 months or 6 months?
Chemotherapy after surgery in stage 3 is usually a combination of two drugs: oxaliplatin with a fluorouracil drip (the FOLFOX regimen) or with capecitabine tablets (the CAPOX regimen) [2]. Oxaliplatin can damage the nerves of the hands and feet (numbness and tingling), and this side effect builds up the longer treatment goes on [2].
In a large analysis of more than 12,000 patients, 3 months of treatment worked as well as 6 months in patients at lower risk, especially with the CAPOX regimen; but in higher-risk patients, 6 months was slightly better. Nerve damage was much less common with 3 months of treatment [7]. After 5 years, the number of patients alive was almost the same with 3 and 6 months of treatment [8].
If you are not fit for oxaliplatin or cannot tolerate it, 6 months of capecitabine tablets or a fluorouracil drip on its own is also an accepted option [2]. Read more: How many chemotherapy sessions will I need? and Numbness and tingling in the hands and feet (neuropathy).
For physicians
IDEA (6 trials, 12,834 patients with stage III): non-inferiority of 3 months was not confirmed in the overall population (DFS HR 1.07; 95% CI 1.00 to 1.15); CAPOX HR 0.95 (0.85 to 1.06) and FOLFOX HR 1.16 (1.06 to 1.26); T1–3 N1: 3-year DFS 83.1% vs 83.3% (HR 1.01; 0.90 to 1.12); T4 and/or N2: 62.7% vs 64.4% (HR 1.12; P=0.01 for superiority of 6 months); grade 2 or higher neurotoxicity with 3 vs 6 months: FOLFOX 16.6% vs 47.7% and CAPOX 14.2% vs 44.9% [7]. Final analysis (median follow-up 72.3 months): 5-year OS 82.4% vs 82.8% (HR 1.02); CAPOX 82.1% vs 81.2% (HR 0.96) and FOLFOX 82.6% vs 83.8% (HR 1.07) [8].
ESMO: CAPOX for 3 or 6 months or FOLFOX for 6 months [I, A]; adapting to risk group (CAPOX 3 months in T1–3 N1; CAPOX or FOLFOX 6 months in T4 or N2) with caution, as it rests on a post hoc analysis [V]; not fit for or intolerant of oxaliplatin: capecitabine or LV5FU2 for 6 months [I, A]; stop oxaliplatin immediately with neuropathy above grade 1; DPD genotyping or phenotyping before a fluoropyrimidine [III, A] [2]. Regimens: CAPOX · FOLFOX · DPYD testing before chemotherapy.
The MSI or MMR test: why does it matter?
After surgery, a test on the tumour sample shows whether the cancer cells have a problem repairing errors in their DNA; this is called MSI-H or dMMR [2]. In one study of patients with stage 2 and 3 cancer, about 1 in 7 patients had such a tumour [5].
- In stage 2: these tumours have a low risk of coming back, and single-drug chemotherapy did not help them; so chemotherapy is usually not needed [2, 3, 5].
- In stage 3: chemotherapy with oxaliplatin is given [2, 3]. In a recent study, adding immunotherapy (atezolizumab) to this chemotherapy halved the risk of the cancer coming back [14].
- Inheritance: this test also helps to find "Lynch syndrome", an inherited tendency to cancer [2]. See Is cancer hereditary?
Read more: MSI-H or dMMR bowel cancer: immunotherapy instead of chemotherapy.
For physicians
ATOMIC (phase 3, 712 patients with stage III dMMR disease; 53.9% T4 and/or N2): atezolizumab with mFOLFOX6 for 6 months, then atezolizumab alone to a total of 12 months, vs mFOLFOX6 alone for 6 months; 3-year DFS 86.3% vs 76.2% (HR 0.50; 95% CI 0.35 to 0.73; P<0.001); grade 3 or 4 adverse events 84.1% vs 71.9% [14]. ESMO: in stage III, the use of MMR status is limited to identifying Lynch syndrome [IV, A], and in localised dMMR disease, if chemotherapy is given, it should always include oxaliplatin [2].
The tumour DNA blood test (ctDNA): does it change the decision?
Cancer cells release tiny pieces of their DNA into the blood. A test that looks for these pieces in the blood a few weeks after surgery (ctDNA) shows whether some cancer is probably still in the body; when the result is positive, the risk of the cancer coming back is much higher [12].
- Stage 2: in one study, when the chemotherapy decision was based on this test, almost half as many patients received chemotherapy, and the results after 5 years were just as good [10, 11].
- Stage 3: in another study, when treatment was made lighter in patients with a negative result, the results were slightly worse than with standard treatment; so in stage 3 this test does not yet replace standard treatment [12].
In 2022, the European Society for Medical Oncology did not recommend routine use of this test to choose treatment, because it had not yet been shown that basing decisions on it improves results [13]. If you have had a ctDNA test, go through the result with your doctor and do not base the decision on it alone. Read more: Liquid biopsy and circulating tumour DNA (ctDNA).
For physicians
DYNAMIC (stage II; 455 patients, randomised 2:1): ctDNA-positive at week 4 or 7 after surgery, oxaliplatin-based or fluoropyrimidine chemotherapy; ctDNA-negative, no treatment. ACT use 15% vs 28% (RR 1.82); 2-year RFS 93.5% vs 92.4% (difference 1.1 percentage points; 95% CI −4.1 to 6.2; non-inferiority margin −8.5); 3-year RFS 86.4% in treated ctDNA-positive patients and 92.5% in untreated ctDNA-negative patients [10]. 5-year follow-up (median 59.7 months): RFS 88% vs 87% and OS 93.8% vs 93.3% (HR 1.05; P=0.887); ctDNA clearance at the end of treatment in 35 of 40 patients [11].
DYNAMIC-III (stage III; 968 evaluable patients, 72.5% ctDNA-negative): 3-year RFS 87% in ctDNA-negative vs 49% in ctDNA-positive patients; in ctDNA-negative patients, de-escalation reduced oxaliplatin use from 88.6% to 34.8% and hospitalisation from 13.2% to 8.5%, but RFS was 85.3% vs 88.1% and the non-inferiority margin was not met; escalation in ctDNA-positive patients brought no benefit (2-year RFS 51% vs 61%); persistent ctDNA after treatment: 3-year RFS 14% vs 79% [12]. ESMO 2022: detection of molecular residual disease has high clinical validity for predicting relapse, but as there is no evidence of clinical utility in directing treatment, it is not recommended for routine practice [13].
Rectal cancer
Treatment of rectal cancer differs from that of colon cancer. In many patients with stage 2 and 3 disease, chemotherapy with radiotherapy, or short-course radiotherapy followed by chemotherapy, is given before surgery; in some lower-risk patients, chemotherapy alone before surgery is enough [15]. In large studies of high-risk patients, giving more of the chemotherapy before surgery lowered the chance of the cancer coming back or spreading [16, 17].
In rectal tumours with MSI-H or dMMR, immunotherapy alone (dostarlimab) cleared the tumour in all 12 patients of a small study, and none of them had needed surgery or radiotherapy at the time of the report [18]. A multidisciplinary team sets each patient's plan. See Colorectal cancer.
For physicians
RAPIDO (912 patients at high risk on MRI): short-course radiotherapy 5 × 5 Gy followed by 6 cycles of CAPOX or 9 cycles of FOLFOX4 before TME; 3-year disease-related treatment failure 23.7% vs 30.4% (HR 0.75) [16]. PRODIGE 23 (461 patients with cT3–4 M0): 6 cycles of mFOLFIRINOX before chemoradiotherapy; 3-year DFS 76% vs 69% (HR 0.69) [17]. Locally advanced dMMR: dostarlimab every 3 weeks for 6 months; clinical complete response in 12 of 12 patients, without chemoradiotherapy or surgery (follow-up 6 to 25 months) [18]. Regimen: Total neoadjuvant therapy (RAPIDO).
Older age and other illnesses
Age alone is not a reason to have or not to have chemotherapy; your doctor weighs up the likely benefit, the risk of the cancer coming back, your general health, other illnesses and life expectancy together [2]. In older people the benefit of chemotherapy is usually smaller and side effects are more likely, and oxaliplatin is given with more caution [2]. Conditions such as severe heart, kidney or liver failure, an uncontrolled infection or severe physical frailty may rule out chemotherapy [2].
For physicians
ESMO: age alone has no predictive value and must be weighed with the potential benefit, the risk of relapse and life expectancy based on biological age and comorbidities; in older patients the benefit of a fluoropyrimidine with or without oxaliplatin is more limited and toxicity more likely. In a pooled analysis of NSABP C-08, XELOXA, X-ACT and AVANT, the overall survival HR with oxaliplatin was 0.78 at age 70 or older and 0.62 in younger patients; in NO16968, HR 0.91 (0.66 to 1.26) at 70 or older vs 0.80 in younger patients. Relative contraindications: ECOG above 2, uncontrolled infection, severe liver and kidney dysfunction and NYHA class III or IV heart failure [2]. Tools: Geriatric assessment before chemotherapy · CARG score.
When is it safe to go without chemotherapy, and when is it not?
Weighed up with your doctor
Leaving it out is dangerous
- Stage 3: chemotherapy prevents 10 to 15 deaths for every 100 patients, and oxaliplatin another 4 to 5 [2]
- Stage 2 with a T4 tumour [3]
Start chemotherapy after surgery as soon as you can; ideally no later than 8 weeks after the operation [2]. In a review of 10 studies with more than 15,000 patients, every 4-week delay in starting chemotherapy was linked to a lower chance of survival [9], and if it starts more than 6 months after surgery, its benefit becomes very small or is lost [2]. If you are worried about side effects, do not drop treatment on your own; talk to your doctor.
Questions to ask your doctor
- "What exactly is the stage of my cancer? How many lymph nodes were examined, and how many contained cancer?"
- "Does my tumour have any high-risk features? What was the result of the MSI or MMR test?"
- "How much does chemotherapy lower the risk of my cancer coming back? Out of 100 patients like me, for how many does it make a difference?"
- "Are 3 months enough for me, or do I need 6? Tablets (capecitabine) or a drip?"
- "Do I need a test for DPD enzyme deficiency before I start?"
- "What happens if I get numbness and tingling in my hands and feet?"
- "Would a ctDNA test help with my decision?"
To prepare, read: What is chemotherapy and how is it given? and Your first chemotherapy session.
Frequently asked questions
Is chemotherapy needed for stage 2 bowel cancer?
How many chemotherapy sessions are there after bowel surgery?
In the CAPOX regimen (capecitabine tablets and oxaliplatin), each cycle lasts 3 weeks, so 3 months of treatment means 4 cycles. In the FOLFOX regimen each cycle lasts 2 weeks, and 6 months of treatment means 12 cycles [8]. Your doctor sets the length of treatment based on the risk of the cancer coming back [2].
Can I take chemotherapy tablets instead of a drip?
In the CAPOX regimen, capecitabine tablets replace the fluorouracil drip, but oxaliplatin is still given by infusion [2]. For people who cannot tolerate oxaliplatin, 6 months of capecitabine tablets alone is an accepted option [2]. See Chemotherapy tablets at home.
What happens if I do not have chemotherapy after surgery?
It depends on the stage. In stage 3, the chance of the cancer coming back is higher; chemotherapy prevents 10 to 15 deaths for every 100 patients, and oxaliplatin another 4 to 5 [2]. In stage 1 and low-risk stage 2, going without chemotherapy usually adds no risk [2, 3]. Make the decision with your doctor.
What is the DPD test and why does it matter?
The DPD enzyme breaks down the drugs fluorouracil and capecitabine in the body. About 3 to 5 in every 100 people lack enough of this enzyme and can develop very severe, even fatal, side effects at the usual dose; that is why testing for it is recommended before treatment starts [2].
If my ctDNA test is negative, does that mean I do not need chemotherapy?
Scientific evidence
Key studies in the evidence library
10 itemsDuration of Adjuvant Chemotherapy for Stage III Colon Cancer
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Related links
Related cancer types
Related questions
References
19 referencesShow all references, 10 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2
- 3
- 4Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
- 5
- 6Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
- 7
- 8
- 9Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis
- 10
- 11
- 12
- 13
- 14Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer
- 15Rectal Cancer Treatment (PDQ®)–Patient Version
- 16Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
- 17Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
- 18PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
- 19
This page is based on reputable scientific sources and was last updated on 29 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/questions/is-chemo-necessary-colon-cancer/